Slide 1: Third Quarter 2018: Trusted by the Life Sciences Industry
Third Quarter 2018 Trusted by the Life Sciences Industry 1
Slide 2: Safe Harbor – Forward Looking Statements
Safe Harbor – Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new strategic opportunities which may include a strategic transaction, plans
Slide 3: Company Overview
Company Overview Leading temperature-controlled logistics solutions provider for the life sciences Business description industry with a focus on the regenerative medicine market (e.g., CAR-T) Pharmaceutical and biotechnology companies (e.g., Novartis, Gilead/Kite, Atara, Zoetis Clients etc.) Markets
Slide 4: Gilead – Yescarta Ramp Builds
Gilead – Yescarta® Ramp Builds Yescarta® approved in U.S. in October 2017 Received EU approval August 27th for relapsed/refractory DLBCL and PMBCL Goal of 20 certified EU centers by end of 2018 $75 million in net commercial Yescarta® revenues in Q3 2018 and $183 million YTD 64 cancer centers authori
Slide 5: Novartis – Kymriah Ramp Continues
Novartis – Kymriah® Ramp Continues Second indication of Kymriah® for adult r/r DLBCL approved in Q2 2018 August 27th received EU approval for r/r pediatric & young adult ALL and r/r DLBCL. September 5th NHS England reaches deal with Novartis for Kymriah ® reimbursement September 6th Kymriah® receive
Slide 6: Clinical Trials Drive Revenue Growth in Biopharma
Clinical Trials Drive Revenue Growth in Biopharma 37 new clinical trials (net) added in Q3-2018; 100 clinical trials (net) added during the last 12 months; 38 Phase III trials 295 38 125 132 6
Slide 7: Primary Target Market: Regenerative Therapy
Primary Target Market: Regenerative Therapy Industry inflection point: Ph. I: 330 Commercialization has begun (261 in 2016) Novartis’ CAR-T drug, KymriahTM , 1003 (192 in 2015) Ph. II: 580 FDA approved in August 2017 and Gilead/Kite therapy, Yescarta™, FDA approved in October 2017 Clinical trials un
Slide 8: Global Transportation Partnerships
Global Transportation Partnerships Cryoport’s solutions have global reach through shipping agreements with FedEx, UPS, DHL, and World Courier 8
Slide 9: Continue to build new partnerships
Continue to build new partnerships • 30 years of expertise and global leadership • 80,000 total stem cell therapies managed • 22,000 cell and blood shipments annually • 6,200 annual stem cell therapies • 19 million donors in world’s largest registry • 250 research studies underway • 900 employees st
Slide 10: Global Distribution of Regenerative Medicine Companies
Global Distribution of Regenerative Medicine Companies
Slide 11: Global Logistics Centers
Global Logistics Centers $10.3 billion raised by Regenerative Medicine industry through Q3 May, 2018 Gilead announced a new YescartaTM manufacturing facility would be built in Amsterdam, Netherlands. July, 2018 Novartis announced KymriahTM manufacturing centers in Paris, France and Leipzig, Germany.
Slide 12: 2018 Clinical Milestones
2018 Clinical Milestones Released data on Presented positive data Received RMAT status in Initiated a rolling Biologics remestemcel-L for the from its Phase 3 trial of the US for ATIR101, and Licensing Application treatment of acute graft its LentiGlobin gene anticipates MAA approval (BLA) for RVT-8
Slide 13: Cryoport's Continuous Vigilance to Minimize Risk and Maximize Success
Cryoport’s Continuous Vigilance to Minimize Risk and Maximize Success 13
Slide 14: Leveraging the Scalable Business Model
Leveraging the Scalable Business Model Continuing strong double-digit growth in revenue, year-over-year and sequentially Net revenue for the nine months ended Gross margin for the nine months ended September 30, 2018 vs. prior year ($mm) September 30, 2018 vs. prior year (%) $13.9M 60.0% + 4PP 53% 5
Slide 15: Financial Performance YTD September 30, 2018
Financial Performance YTD September 30, 2018 Statements of Operations Data: 9 months 9 months growth % (in thousands) 2015 2016 2017 2017 2018 Net Revenues $ 5,525 $ 7,679 $ 11,954 $ 8,632 $ 13,936 61.4% Biopharma 3,364 5,302 9,113 6,597 11,603 75.9% Animal Health 869 845 1,135 782 748 -4.3% Reprodc
Slide 16: Quarterly Revenue Trends
Quarterly Revenue Trends Continued quarterly revenue growth fueled by revenue expansion from existing clients and new client acquisitions $5.3M $4.6M $4.0M $3.3M $3.0M Q3-2018 over Q3-2017 growth: 76% Sequential growth: 14.0% 16
Slide 17: Quarterly Revenue Trends (cont'd)
Quarterly Revenue Trends (cont’d) Biopharma growth continues to be driven by ramp in clinical trials supported and commencement of revenue from the support of commercials therapy launches Q3-2018 over Q3-2017 growth: +90.7% +42.7% -7.5% 17
Slide 18: Quarterly Revenue Trends
Quarterly Revenue Trends The biopharma market now represents 85% of total revenue, growing 91% compared to 2017 11% 4% 14% +76% Total Revenue Growth 8% 78% +91% Biopharma 85% Revenue Growth 18
Slide 19: Financial Highlights: Q3-2018
Financial Highlights: Q3-2018 Revenue Biopharma Supporting revenue 38 Phase III $5.3M 295 clinical trials trials up 76% up 91% Reproductive Gross $550,000 revenue from Medicine Margin commercial agreements 52% up 43% Strong embedded growth Adjusted EBITDA with existing clients improved by 48% $24M C
Slide 20: Thank you!
Science. Logistics. Certainty. Thank you! 20 NASDAQ: CYRX